t
ECO Animal Health Group plc, on 25 September 2025, provided a trading update for the six months ending 30 September 2025, projecting over 15% revenue growth (vs H1 2025: £33.2 million) and a material increase in adjusted EBITDA (vs H1 2025: £0.4 million), driven by segment growth including China/Japan (>40%) and North America (>25%). The company also stated its interim results for this period will be announced in late November 2025.
| Date | 25 Sept 2025 |
| Time | 07:00:13 |
| Category | Results |
| ID | 7127A |
25 September 2025
ECO Animal Health Group plc
("ECO" or the "Company")
AGM Trading Update and Notice of Interim Results
Strong trading year to date, strongly ahead of prior year
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the following trading update for the six months ending 30 September 2025, ahead of its Annual General Meeting being held at 9.00 a.m. this morning.
Trading Update
Trading in the first half of this financial year has been significantly stronger compared to the same period last year despite currency headwinds and tariff challenges, with an expected increase in revenue of over 15% (H1 2025: £33.2 million). This revenue strength has been particularly evident in the China/Japan segment (greater than 40% growth) and North America (greater than 25% growth). Continuing strength in Brazil has been offset by some weakness elsewhere in Latin America. The South East Asia region has recovered much of the ground lost in the prior year.
The Company also expects to report improved gross margins for the period, which will translate into a material increase in adjusted EBITDA compared with the first half of the prior year (H1 2025: £0.4 million).
It is expected that this strength in the first half will result in a more balanced first and second half weighting than has been experienced in recent years and provides the Board with increased confidence of a successful full year outcome in line with current market expectations.1
Interim Results
The Company's interim results for the six-month period ending 30 September 2025 will be announced in late November 2025.
1 The consensus market expectations for revenue and adjusted EBITDA for the year ending 31 March 2026 are £84.2m and £7.9m respectively.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com